Cargando…
Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase
OBJECTIVES: Herein, we describe the epidemiology of carbapenemase-producing Enterobacterales (CPE) before and during the COVID-19 pandemic. Also, we report the emergence of an outbreak of Klebsiella pneumoniae strains co-producing KPC and OXA-181 carbapenemase, resistant to novel β-lactam/β-lactamas...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433922/ https://www.ncbi.nlm.nih.gov/pubmed/37600494 http://dx.doi.org/10.1093/jacamr/dlad099 |
_version_ | 1785091759921954816 |
---|---|
author | Bovo, Federica Amadesi, Stefano Palombo, Marta Lazzarotto, Tiziana Ambretti, Simone Gaibani, Paolo |
author_facet | Bovo, Federica Amadesi, Stefano Palombo, Marta Lazzarotto, Tiziana Ambretti, Simone Gaibani, Paolo |
author_sort | Bovo, Federica |
collection | PubMed |
description | OBJECTIVES: Herein, we describe the epidemiology of carbapenemase-producing Enterobacterales (CPE) before and during the COVID-19 pandemic. Also, we report the emergence of an outbreak of Klebsiella pneumoniae strains co-producing KPC and OXA-181 carbapenemase, resistant to novel β-lactam/β-lactamase inhibitors (βL-βLICs) and cefiderocol. METHODS: CPE were collected during a period of 3 years from 2019 to 2021. Antimicrobial susceptibility testing for novel βL-βLICs and cefiderocol was performed by MIC test strips and microdilution with iron-depleted broth. WGS was performed on 10 selected isolates using the Illumina platform, and resistome analysis was carried out by a web-based pipeline. RESULTS: Between January 2019 and December 2021, we collected 1430 carbapenemase producers from 957 patients with infections due to CPE. KPC was the most common carbapenemase, followed by VIM, OXA-48 and NDM. During 2021, we identified 78 K. pneumoniae co-producing KPC and OXA-181 carbapenemases in 60 patients, resistant to meropenem/vaborbactam and imipenem/relebactam. Resistance to ceftazidime/avibactam and cefiderocol was observed respectively in 7 and 8 out of the 10 sequenced K. pneumoniae. Genome analysis showed that all isolates were clonally related, shared a common porin and plasmid content, and carried bla(OXA-181) and bla(KPC) carbapenemases. Specifically, 4 out of 10 isolates carried bla(KPC-3), while 6 harboured mutated bla(KPC). Of note, KPC producers resistant to ceftazidime/avibactam and harbouring mutated bla(KPC) exhibited higher MICs of cefiderocol (median MIC 16 mg/L, IQR 16–16) than strains harbouring WT bla(KPC-3) (cefiderocol 9 mg/L, IQR 1.5–16). CONCLUSIONS: Our results highlight the need for continuous monitoring of CPE to limit widespread MDR pathogens carrying multiple mechanisms conferring resistance to novel antimicrobial molecules. |
format | Online Article Text |
id | pubmed-10433922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-104339222023-08-18 Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase Bovo, Federica Amadesi, Stefano Palombo, Marta Lazzarotto, Tiziana Ambretti, Simone Gaibani, Paolo JAC Antimicrob Resist Original Article OBJECTIVES: Herein, we describe the epidemiology of carbapenemase-producing Enterobacterales (CPE) before and during the COVID-19 pandemic. Also, we report the emergence of an outbreak of Klebsiella pneumoniae strains co-producing KPC and OXA-181 carbapenemase, resistant to novel β-lactam/β-lactamase inhibitors (βL-βLICs) and cefiderocol. METHODS: CPE were collected during a period of 3 years from 2019 to 2021. Antimicrobial susceptibility testing for novel βL-βLICs and cefiderocol was performed by MIC test strips and microdilution with iron-depleted broth. WGS was performed on 10 selected isolates using the Illumina platform, and resistome analysis was carried out by a web-based pipeline. RESULTS: Between January 2019 and December 2021, we collected 1430 carbapenemase producers from 957 patients with infections due to CPE. KPC was the most common carbapenemase, followed by VIM, OXA-48 and NDM. During 2021, we identified 78 K. pneumoniae co-producing KPC and OXA-181 carbapenemases in 60 patients, resistant to meropenem/vaborbactam and imipenem/relebactam. Resistance to ceftazidime/avibactam and cefiderocol was observed respectively in 7 and 8 out of the 10 sequenced K. pneumoniae. Genome analysis showed that all isolates were clonally related, shared a common porin and plasmid content, and carried bla(OXA-181) and bla(KPC) carbapenemases. Specifically, 4 out of 10 isolates carried bla(KPC-3), while 6 harboured mutated bla(KPC). Of note, KPC producers resistant to ceftazidime/avibactam and harbouring mutated bla(KPC) exhibited higher MICs of cefiderocol (median MIC 16 mg/L, IQR 16–16) than strains harbouring WT bla(KPC-3) (cefiderocol 9 mg/L, IQR 1.5–16). CONCLUSIONS: Our results highlight the need for continuous monitoring of CPE to limit widespread MDR pathogens carrying multiple mechanisms conferring resistance to novel antimicrobial molecules. Oxford University Press 2023-08-17 /pmc/articles/PMC10433922/ /pubmed/37600494 http://dx.doi.org/10.1093/jacamr/dlad099 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Bovo, Federica Amadesi, Stefano Palombo, Marta Lazzarotto, Tiziana Ambretti, Simone Gaibani, Paolo Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase |
title | Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase |
title_full | Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase |
title_fullStr | Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase |
title_full_unstemmed | Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase |
title_short | Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase |
title_sort | clonal dissemination of klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing kpc and oxa-181 carbapenemase |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433922/ https://www.ncbi.nlm.nih.gov/pubmed/37600494 http://dx.doi.org/10.1093/jacamr/dlad099 |
work_keys_str_mv | AT bovofederica clonaldisseminationofklebsiellapneumoniaeresistanttocefiderocolceftazidimeavibactammeropenemvaborbactamandimipenemrelebactamcoproducingkpcandoxa181carbapenemase AT amadesistefano clonaldisseminationofklebsiellapneumoniaeresistanttocefiderocolceftazidimeavibactammeropenemvaborbactamandimipenemrelebactamcoproducingkpcandoxa181carbapenemase AT palombomarta clonaldisseminationofklebsiellapneumoniaeresistanttocefiderocolceftazidimeavibactammeropenemvaborbactamandimipenemrelebactamcoproducingkpcandoxa181carbapenemase AT lazzarottotiziana clonaldisseminationofklebsiellapneumoniaeresistanttocefiderocolceftazidimeavibactammeropenemvaborbactamandimipenemrelebactamcoproducingkpcandoxa181carbapenemase AT ambrettisimone clonaldisseminationofklebsiellapneumoniaeresistanttocefiderocolceftazidimeavibactammeropenemvaborbactamandimipenemrelebactamcoproducingkpcandoxa181carbapenemase AT gaibanipaolo clonaldisseminationofklebsiellapneumoniaeresistanttocefiderocolceftazidimeavibactammeropenemvaborbactamandimipenemrelebactamcoproducingkpcandoxa181carbapenemase |